• Afhalen na 1 uur in een winkel met voorraad
  • Gratis thuislevering in België vanaf € 30
  • Ruim aanbod met 7 miljoen producten
  • Afhalen na 1 uur in een winkel met voorraad
  • Gratis thuislevering in België vanaf € 30
  • Ruim aanbod met 7 miljoen producten
  1. Boeken
  2. Non-fictie
  3. Wetenschap
  4. Geneeskunde
  5. Access to Non-Summary Clinical Trial Data for Research Purposes Under EU Law

Access to Non-Summary Clinical Trial Data for Research Purposes Under EU Law

Daria Kim
Paperback | Engels | Munich Studies on Innovation and Competition | nr. 16
€ 137,45
+ 274 punten
Uitvoering
Levertermijn 1 à 4 weken
Eenvoudig bestellen
Veilig betalen
Gratis thuislevering vanaf € 30 (via bpost)
Gratis levering in je Standaard Boekhandel

Omschrijving

This book draws a unique perspective on the regulation of access to clinical trial data as a case on research and knowledge externalities. Notwithstanding numerous potential benefits for medical research and public health, many jurisdictions have struggled to ensure access to clinical trial data, even at the level of the trial results. Pro-access policy initiatives have been strongly opposed by research-based drug companies arguing that mandatory data disclosure impedes their innovation incentives. Conventionally, access to test data has been approached from the perspective of transparency and research ethics. The book offers a complementary view and considers access to individual patient-level trial data for exploratory analysis as a matter of research and innovation policy. Such approach appears to be especially relevant in the data-driven economy where digital data constitutes a valuable economic resource. The study seeks to define how the rules of access to clinical trial data should be designed to reconcile the policy objectives of leveraging the research potential of data through secondary analysis, on the one hand, and protecting economic incentives of research-based drug companies, on the other hand. Overall, it is argued that the mainstream innovation-based justification for exclusive control over the outcomes of research and development can hardly rationalise trial sponsors' control over primary data from trials. Instead, access to such data and its robust analysis should be prioritised.

Specificaties

Betrokkenen

Auteur(s):
Uitgeverij:

Inhoud

Aantal bladzijden:
300
Taal:
Engels
Reeks:
Reeksnummer:
nr. 16

Eigenschappen

Productcode (EAN):
9783030867805
Verschijningsdatum:
21/10/2022
Uitvoering:
Paperback
Formaat:
Trade paperback (VS)
Afmetingen:
156 mm x 234 mm
Gewicht:
449 g
Standaard Boekhandel

Alleen bij Standaard Boekhandel

+ 274 punten op je klantenkaart van Standaard Boekhandel
E-BOOK ACTIE

Tot meer dan 50% korting

op een selectie e-books
E-BOOK ACTIE
E-book kortingen
Standaard Boekhandel

Beoordelingen

We publiceren alleen reviews die voldoen aan de voorwaarden voor reviews. Bekijk onze voorwaarden voor reviews.